Breaking News

WuXi Biologics Recognized as ESG Leader by Morningstar Sustainalytics

Marks the sixth consecutive year that WuXi Biologics has received this honor

WuXi Biologics, a global Contract Research, Development and Manufacturing Organization (CRDMO), has been named by Morningstar Sustainalytics as both an Industry ESG Leader and a Regional ESG Leader for 2026.

Marking the sixth consecutive year that WuXi Biologics has received this honor, the recognition highlights the company’s commitment to advancing sustainability throughout its global business operations and value chain and demonstrates the success of its long-term sustainability strategy and its vision as a Green CRDMO leader.

Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, said, “We are honored to once again be recognized by Morningstar Sustainalytics. As a proactive leader in sustainability, we are committed to collaborating with all stakeholders to create positive social and environmental impacts, empowering our global clients through end-to-end Green CRDMO solutions, and advancing responsible practices across the entire value chain.”

Learn how companies throughout the pharma industry are securing sustainability in the supply chain.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters